# Moyamoya Vasculopathy and Atypical Moyamoya-like Patterns: Insights into Diagnosis and Therapeutic Implications

**Authors:** Rosalinda Calandrelli, Carlo Augusto Mallio, Caterina Bernetti, Luca Massimi, Fabio Pilato

PMC · DOI: 10.3390/neurosci7010027 · NeuroSci · 2026-02-15

## TL;DR

This review explores Moyamoya vasculopathy, focusing on diagnostic challenges and treatment approaches for different subtypes and atypical patterns.

## Contribution

The paper provides updated insights into diagnostic debates and therapeutic implications for Moyamoya vasculopathy and its variants.

## Key findings

- Moyamoya Disease (MMD) typically involves bilateral steno-occlusion of arteries with characteristic collaterals.
- Moyamoya Syndrome (MMS) often presents with unilateral patterns and fewer collaterals, influenced by underlying conditions.
- Atypical moyamoya-like patterns complicate diagnosis and require multimodal imaging and genetic data for accurate differentiation.

## Abstract

Purpose: The aim of this narrative review is to update current knowledge on Moyamoya vasculopathy (MMV) by addressing key diagnostic debates—including laterality; genetic subtypes; regional epidemiology; and features distinguishing Moyamoya Disease (MMD), Moyamoya Syndrome (MMS) and their mimics. Methods: Key and representative studies were identified through PubMed/MEDLINE and Scopus, focusing on publications from 2014–2025 while also considering earlier seminal works. Results: MMD typically presents with bilateral steno-occlusion of the terminal internal carotid arteries (ICAs) and proximal middle and anterior cerebral arteries (MCAs/ACAs) due to concentric vascular thickening, accompanied by characteristic ‘puff-of-smoke’ collaterals, whereas MMS shows a similar but more often unilateral pattern with fewer collaterals, influenced by the underlying condition. However, this distinction often fails to reflect the full clinical and radiological variability of the Moyamoya spectrum. Atypical moyamoya-like patterns, often confined to M1 or A1 segments, further complicate diagnosis. Clinical manifestations ranged from asymptomatic cases to ischemic or hemorrhagic strokes, and occasionally seizures. Diagnosis relied on multimodal imaging (DSA, MRA, CTA), but genetic mutations, contributing to radiological variability, often complicate differentiation between MMD, MMS, and mimics. Management is pattern-specific: MMS and atypical forms are generally managed conservatively, whereas MMD frequently requires surgical revascularization, particularly in children and symptomatic adults. Nevertheless, variability within diagnostic categories limits the applicability of rigid treatment protocols. Conclusions: Current diagnostic algorithms remain limited. Integrating advanced imaging findings with clinical, genetic, and epidemiological data is essential to define the full disease spectrum, improve diagnostic accuracy, and inform patient management and outcome assessment.

## Linked entities

- **Diseases:** Moyamoya Disease (MONDO:0016820)

## Full-text entities

- **Genes:** RNF213 (ring finger protein 213) [NCBI Gene 57674] {aka ALO17, C17orf27, KIAA1618, MYMY2, MYSTR, NET57}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, ACTA2 (actin alpha 2, smooth muscle) [NCBI Gene 59] {aka ACTSA, SMDYS}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, S100A4 (S100 calcium binding protein A4) [NCBI Gene 6275] {aka 18A2, 42A, CAPL, FSP1, MTS1, P9KA}, GUCY1A1 (guanylate cyclase 1 soluble subunit alpha 1) [NCBI Gene 2982] {aka GC-S-alpha-1, GC-SA3, GCS-alpha-3, GUC1A3, GUCA3, GUCSA3}, NF1 (neurofibromin 1) [NCBI Gene 4763] {aka NFNS, VRNF, WSS}
- **Diseases:** necrosis (MESH:D009336), developmental delays (MESH:D002658), Vascular Anomalies (MESH:D020785), endothelial hyperplasia (MESH:D006965), facial pain (MESH:D005157), Ap (MESH:D018420), Seizures (MESH:D012640), metabolic diseases (MESH:D008659), genetic or (MESH:D030342), Turner syndrome (MESH:D014424), M1 occlusion (MESH:D015470), hypotension (MESH:D007022), ischemia (MESH:D007511), AVMs (MESH:C564254), neurological deficits (MESH:D009461), intracranial stenosis (MESH:D003251), chronic (MESH:D002908), brain tumors (MESH:D001932), Congenital disorders (MESH:D009358), cognitive decline (MESH:D003072), hemorrhage (MESH:D006470), scalp necrosis (MESH:D004476), AVM (MESH:D001165), autoimmune diseases (MESH:D001327), infarct (MESH:D007238), language disturbance (MESH:D007806), Ischemic Attack (MESH:D002546), intracranial hemorrhage (MESH:D020300), hypercapnic (MESH:D012131), MMV (MESH:D009072), stroke (MESH:D020521), muscle loss (MESH:D009135), thromboembolic (MESH:D013923), chromosomal abnormalities (MESH:D002869), Ischemic stroke (MESH:D002544), neoplasms (MESH:D009369), vessel rupture (MESH:D012421), diabetes (MESH:D003920), ischemic (MESH:D002545), vascular abnormalities (MESH:D014652), Down syndrome (MESH:D004314), ischemic lesion (MESH:D017202), arterial stenosis (MESH:D012078), cranial trauma (MESH:D020197), infection (MESH:D007239), vasculopathies (MESH:D000090122), aneurysm (MESH:D000783), loss of consciousness (MESH:D014474), Ap/T-MCA (MESH:C536482), tinnitus (MESH:D014012), atrophy (MESH:D001284), atrophic (MESH:D020966), hemorrhagic stroke (MESH:D000083302), neurological complications (MESH:D002493), aphasia (MESH:D001037), PCA (MESH:D020762), drug toxicity (MESH:D064420), CVR impairment (MESH:D002561), vascular dysplasia (MESH:D057772), hemiparesis (MESH:D010291)
- **Chemicals:** lipid (MESH:D008055), MTT (MESH:C070243), acetazolamide (MESH:D000086), oxygen (MESH:D010100)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** R4810K

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12922065/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12922065/full.md

## References

139 references — full list in the complete paper: https://tomesphere.com/paper/PMC12922065/full.md

---
Source: https://tomesphere.com/paper/PMC12922065